Engineered immune cells take aim at rare Organ-Damaging disease
NCT ID NCT07626476
First seen Jun 06, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This early-phase trial tests a personalized cell therapy called BCMA-targeted CAR-T cells in 30 adults with relapsed or refractory light chain amyloidosis, a rare disease where abnormal proteins build up in organs. The treatment uses the patient's own immune cells, modified to attack the cells producing those proteins. The main goals are to check safety and see if it can reduce disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, Fengtai District, 100070, China
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCMA-targeted CAR-T cells (a personalized immune cell therapy made from the patient's own blood)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat light chain amyloidosis, potentially reducing harmful protein buildup in organs.
What could go wrong
This is a very early, small trial (30 people) focused on safety. CAR-T therapy can cause serious side effects like cytokine release syndrome and infections. It may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.